Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Veracyte (VCYT) Change in Accured Expenses: 2011-2024

Historic Change in Accured Expenses for Veracyte (VCYT) over the last 14 years, with Dec 2024 value amounting to $3.5 million.

  • Veracyte's Change in Accured Expenses rose 45525.00% to $9.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.7 million, marking a year-over-year increase of 1.01%. This contributed to the annual value of $3.5 million for FY2024, which is 623.82% up from last year.
  • Per Veracyte's latest filing, its Change in Accured Expenses stood at $3.5 million for FY2024, which was up 623.82% from -$676,000 recorded in FY2023.
  • In the past 5 years, Veracyte's Change in Accured Expenses ranged from a high of $14.4 million in FY2021 and a low of -$3.9 million during FY2022.
  • Its 3-year average for Change in Accured Expenses is -$351,667, with a median of -$676,000 in 2023.
  • Per our database at Business Quant, Veracyte's Change in Accured Expenses surged by 1,761.87% in 2021 and then plummeted by 127.18% in 2022.
  • Yearly analysis of 5 years shows Veracyte's Change in Accured Expenses stood at -$868,000 in 2020, then surged by 1,761.87% to $14.4 million in 2021, then crashed by 127.18% to -$3.9 million in 2022, then skyrocketed by 82.76% to -$676,000 in 2023, then spiked by 623.82% to $3.5 million in 2024.